Biogen’s gamble on multiple sclerosis drug opicinumab looks increasingly ... after patients switched from reference anti-TNF products to a biosimilar, which could help assuage the fears of ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

On a call with analysts, Chief Executive Chris Viehbacher said the four products launched ... are a key part of Biogen's strategy to combat the increased competition in the MS space.

"What we're all about in the near-term is trying to make sure that the revenue (from new products ... multiple sclerosis product decline," Viehbacher told analysts on a conference call. Biogen ...

Biogen expects revenue to decline by a "mid-single digit" percentage in 2025 compared to 2024, as sales of its multiple sclerosis products fall. That portion of the business has declined for ...

saying multiple-sclerosis drug sales will decline further and will only be partially offset by new products. Competition, including from cheap generics, has weighed on Biogen’s costly MS drugs.